Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
van Wilpe S, Simnica D, Slootbeek P, van Ee T, Pamidimarri Naga S, Gorris MAJ, van der Woude LL, Sultan S, Koornstra RHT, van Oort IM, Gerritsen WR, Kroeze LI, Simons M, van Leenders GJLH, Binder M, de Vries IJM, Mehra N.
van Wilpe S, et al. Among authors: pamidimarri naga s.
Oncoimmunology. 2022 Jul 1;11(1):2094133. doi: 10.1080/2162402X.2022.2094133. eCollection 2022.
Oncoimmunology. 2022.
PMID: 35800157
Free PMC article.